Package Leaflet: Information for the User
Movalis 15 mg Tablets
meloxicam
Read this leaflet carefully before you start to take this medicine because it contains important information for you.
Movalis contains the active ingredient meloxicam. Meloxicam belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs) used to reduce inflammation and pain in joints and muscles.
Movalis tablets are indicated for adults and children 16 years of age and older.
Movalis is used for:
-treatment of short-term duration of osteoarthritis crises
-long-term treatment of
-rheumatoid arthritis
-ankylosing spondylitis
Do not take Movalis:
-if you are allergic to meloxicam or any of the other ingredients in this medication (listed in section 6)
-in the last three months of pregnancy
-children and adolescents under 16 years of age
-if you have had any of the following conditions after taking aspirin or other NSAIDs:
- wheezing (asthma), chest tightness, shortness of breath
- nasal congestion due to inflammation of the nasal passages (nasal polyps)
- skin rashes/urticaria
- sudden inflammation of the skin or mucous membranes, such as inflammation around the eyes, face, lips, mouth, or throat, which may make breathing difficult (angioedema)
-if after a previous treatment with NSAIDs you experienced:
- bleeding in your stomach or intestines
- holes (perforations) in your stomach or intestines
-ulcers or bleeding in your stomach or intestines
-if you have had stomach ulcers or bleeding (ulcers or bleeding that have occurred at least twice)
-severe liver dysfunction
-severe kidney failure not on dialysis
-recent bleeding in the brain (cerebrovascular hemorrhage)
-any type of bleeding disorder
-severe heart failure
-intolerance to some sugars since this medication contains lactose (see also "Movalis contains lactose and sodium")
If you are unsure about any of the above situations, please contact your doctor.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Movalis.
Warnings
Medications like Movalis may be associated with a slight increase in the risk of heart attack ("myocardial infarction") or stroke ("cerebral infarction"). Any risk is greater at high doses and with prolonged treatment. Do not take more than the recommended dose. Do not take Movalis for longer than prescribed (see section 3 "How to take Movalis").
If you have heart problems, a previous stroke, or if you think you may be at risk of these diseases, you should discuss treatment with your doctor or pharmacist. For example, if you:
- have high blood pressure (hypertension)
- have high blood sugar levels (diabetes mellitus)
- have high cholesterol levels in the blood (hypercholesterolemia)
- are a smoker
Stop taking Movalis immediately as soon as you notice bleeding (causing black stools) or ulcers in your digestive tract (causing abdominal pain).
Severe skin rashes that can be life-threatening (Stevens-Johnson syndrome, toxic epidermal necrolysis) have been described with the use of Movalis, appearing initially as red circular spots, often with a central blister. Other additional signs that may appear are mouth sores, throat, nose, genital, and conjunctivitis (swollen and red eyes). These skin rashes that can be life-threatening often accompany flu-like symptoms. The rash may progress to form widespread blisters or skin peeling. The period of greatest risk of developing severe skin reactions is during the first weeks of treatment. If you have developed Stevens-Johnson syndrome or toxic epidermal necrolysis with the use of Movalis, do not use Movalis again at any time.
Consult your doctor or pharmacist before starting to take Movalis if you have ever experienced a fixed drug eruption (round or oval-shaped plaques with redness and swelling of the skin that usually reappear in the same place, blistering, urticaria, and itching) after taking meloxicam or other oxicam derivatives (e.g., piroxicam).
If you develop a rash or these symptoms on your skin, stop taking Movalis, go immediately to a doctor, and inform them that you are taking this medication.
Movalis is not suitable if you need to relieve acute pain immediately.
Movalis may mask the symptoms of an infection (e.g., fever). If you think you may have an infection, you should see a doctor.
Precautions for use
Since treatment will need to be adjusted, it is essential to seek advice from your doctor before taking Movalis in the following cases:
Your doctor will need to monitor your progress during treatment.
Taking Movalis with other medications
Since Movalis may affect or be affected by other medications, inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
Specifically, please inform your doctor or pharmacist if you are taking/have taken or have used any of the following medications:
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
Do not take Movalis if you are in the last 3 months of pregnancy, as it may harm the fetus or cause problems during delivery. It may cause kidney and heart problems in your fetus. It may affect your tendency and that of your baby to bleed and delay or prolong delivery.
Do not take Movalis during the first 6 months of pregnancy unless it is clearly necessary and as indicated by your doctor. If you need treatment during this period or while trying to become pregnant, you should take the minimum dose for the shortest possible time. From week 20 of pregnancy, Movalis may cause kidney problems in your fetus if taken for more than a few days, which may cause low amniotic fluid levels surrounding the baby (oligohydramnios) or narrowing of a blood vessel (ductus arteriosus) in the baby's heart. If you need treatment for more than a few days, your doctor may recommend additional monitoring.
If you have taken this medication while pregnant, you should speak immediately with your doctor/midwife to consider adequate monitoring.
Breastfeeding
This medication is not recommended during breastfeeding.
Fertility
This medication may make it more difficult for you to become pregnant. You should inform your doctor if you are planning to become pregnant or if you have difficulty becoming pregnant.
Driving and operating machinery
This medication may cause visual disturbances, including blurred vision, dizziness, sleepiness, vertigo, or other central nervous system disturbances. If you notice these effects, do not drive or operate machinery.
Movalis contains lactose and sodium
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially "sodium-free".
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
The recommended dose is:
Osteoarthritis crisis:
7.5 mg (half tablet) once a day. This can be increased to 15 mg (one tablet) once a day.
Rheumatoid arthritis:
15 mg (one tablet) once a day. This can be reduced to 7.5 mg (half tablet) once a day.
Ankylosing spondylitis:
15 mg (one tablet) once a day. This can be reduced to 7.5 mg (half tablet) once a day.
Do not exceed the maximum recommended dose of 15 mg per day.
If any of the situations described under the title “Warnings and precautions” affect you, your doctor may limit your dose to 7.5 mg (half tablet) once a day.
Older adults
If you are an older adult, the recommended dose in long-term treatment for rheumatoid arthritis and ankylosing spondylitis is 7.5 mg (half tablet) once a day.
Patients at increased risk of adverse reactions
If you are a patient at increased risk of adverse reactions, your doctor will start treatment at a dose of 7.5 mg (half tablet) per day.
Renal insufficiency
If you are a patient on dialysis with severe renal insufficiency, your dose should not exceed 7.5 mg (half tablet) per day. In patients with mild to moderate renal insufficiency, dose reduction is not necessary.
Liver insufficiency
In patients with mild to moderate liver insufficiency, dose reduction is not necessary.
Use in children and adolescents
Movalis should not be administered to children and adolescents under 16 years old.
Consult your doctor or pharmacist if you estimate that Movalis' action is too strong or too weak, or if after several days you do not notice any improvement.
Administration form
Oral route.
Tablets should be swallowed with water or another beverage during meals.
Tablets can be divided into equal doses. The tablet should be divided with the hand and not with a cutting object (e.g. a knife).
If you take more Movalis than you should
If you have taken too many tablets or suspect an overdose, contact your doctor or go to the nearest hospital immediately.
Symptoms associated with acute overdose of NSAIDs are usually limited to:
-lack of energy (lethargy)
-sleep
-nausea and vomiting
-stomach pain (epigastric pain)
These symptoms usually improve when Movalis is stopped. Gastrointestinal bleeding may occur.
Severe intoxication may cause severe adverse reactions (see section 4):
-high blood pressure (hypertension)
-acute kidney failure (renal failure)
-liver dysfunction (hepatic dysfunction)
-respiratory depression (respiratory depression)
-loss of consciousness (coma)
-seizures (convulsions)
-cardiovascular collapse (cardiovascular collapse)
-cardiac arrest (cardiac arrest)
-immediate allergic reactions (hypersensitivity), including:
- fainting
- shortness of breath
- skin reactions
If you forgot to take Movalis
Donot take a double dose to compensate for the missed doses. Simply take the next dose at the usual time.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Stop taking Movalis and consult your doctor or the nearest hospital immediately if you notice:
Any allergic reaction (hypersensitivity) that may appear in the form of:
Multiform erythema is a severe skin allergic reaction that causes patches, red rashes or purple areas with blisters. It can also affect the mouth, eyes, and other moist areas of the body.
-skin or mucous membrane inflammation such as inflammation around the eyes, face, and lips, mouth or throat, possibly making it difficult to breathe, swollen ankles/legs (lower extremity edema)
-difficulty breathing or asthma attacks
-inflammation of the liver (hepatitis). This can cause symptoms such as:
-yellowing of the skin and eyes (jaundice)
-abdominal pain
-loss of appetite
Any gastrointestinal side effect, especially:
Gastrointestinal bleeding (gastrointestinal hemorrhage), ulcer formation or a hole in the digestive tract (perforation) can sometimes be severe and potentially life-threatening, especially in older people.
If you have previously experienced any gastrointestinal symptoms due to long-term use of NSAIDs, seek medical advice immediately, especially if you are an older person. Your doctor may monitor your progress while you are on treatment.
If you experience vision changes, do not drive or use machines.
General side effects of nonsteroidal anti-inflammatory drugs (NSAIDs)
The use of some nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with a slight increase in the risk of arterial occlusion (arterial thrombotic events), such as heart attack (myocardial infarction) or stroke (apoplexy), particularly at high doses and with long-term treatment.
Cases of fluid retention (edema), high blood pressure (hypertension), and heart failure (cardiac failure) have been reported associated with NSAID treatment.
The most common adverse reactions observed affect the gastrointestinal tract (gastrointestinal events):
-stomach and upper small intestine ulcers (peptic/gastroduodenal ulcers)
-a hole in the intestinal wall (perforation) or gastrointestinal bleeding (sometimes fatal, especially in older people)
After NSAID administration, the following adverse reactions have been reported:
- nausea and vomiting
- liquid stools (diarrhea)
- flatulence
- constipation
- indigestion (dyspepsia)
- abdominal pain
- black stools due to gastrointestinal bleeding (melena)
- vomiting blood (hematemesis)
- inflammation with ulcer formation in the mouth (ulcerative stomatitis)
- worsening of gastrointestinal inflammation (e.g., exacerbation of colitis or Crohn's disease)
Less frequently, gastric inflammation (gastritis) has been observed.
Side effects of meloxicam - active substance of Movalis
Very common: can affect more than 1 in 10 people
Common: can affect up to 1 in 10 people
Uncommon: can affect up to 1 in 100 people
Rare: can affect up to 1 in 1,000 people
These side effects can increase the risk of infection and cause symptoms such as bruises or nosebleeds.
Very rare: can affect up to 1 in 10,000 people
Multiform erythema is a severe skin allergic reaction that causes patches, red rashes or purple areas with blisters. It can also affect the mouth, eyes, and other moist areas of the body.
-inflammation of the liver (hepatitis). This can cause symptoms such as:
yellowing of the skin and eyes (jaundice)
abdominal pain
loss of appetite
Frequency not known: the frequency cannot be estimated from available data
Side effects caused by other nonsteroidal anti-inflammatory drugs (NSAIDs), which have not been seen after taking Movalis
Changes in kidney structure that cause acute kidney failure:
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Vigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister pack and on the outer packaging. The expiration date is the last day of the month indicated.
Store in the original packaging to protect it from moisture.Do not store at a temperature above 30°C.
Medications should not be disposed of through drains or in the trash. Dispose of containers and medications you no longer need at the SIGRE drop-off point at the pharmacy. If in doubt, ask your pharmacist how to dispose of containers and medications you no longer need. By doing so, you will help protect the environment.
Composition of Movalis
The active ingredient is:
-meloxicam
-one tablet contains 15 mg of meloxicam
The other components are:
-sodium citrate
-lactose monohydrate
-microcrystalline cellulose
-povidone
-anhydrous colloidal silica
-crospovidone
-magnesium stearate
Appearance of the product and contents of the package
Movalis is a yellowish clear round tablet with the company logo on one side and a mark with 77C/77C on the other. Each Movalis tablet has a notch and can be divided into two equal halves.
Movalis is available in PVC/PVDC/Aluminum blisters.
Package sizes:boxes of 1, 2, 7, 10, 14, 15, 20, 28, 30, 50, 60, 100, 140, 280, 300, 500, 1,000 tablets.
Only some package sizes may be commercially available.
Other presentations of Movalis and other forms of meloxicam administration
Meloxicam is also available in some countries as:
-meloxicam 7.5 mg tablets
-meloxicam 15 mg/1.5 ml injectable solution
Marketing authorization holder and manufacturer
Marketing authorization holder:
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Manufacturer:
Boehringer Ingelheim Hellas Single Member S.A.
5th km Paiania – Markopoulo
194 41 Koropi, Attiki
Greece
Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Strasse 173,
55216 Ingelheim am Rhein
Germany
Rottendorf Pharma GmbH
Ostenfelder Strasse 51 - 61
59320 Ennigerloh
Germany
Local representative:
Boehringer Ingelheim España, S.A.
Prat de la Riba, 50
08174 Sant Cugat del Vallès (Barcelona)
Spain
This medicine is authorized in the member states of the European Economic Area with the following names:
Austria, Bulgaria, Croatia, Estonia, Hungary, Latvia, Lithuania, Poland, Portugal, Romania, Slovakia, Slovenia, Spain: Movalis®
Belgium, Finland, France, Italy, Luxembourg: Mobic®
Cyprus, Greece: Movatec®
Germany: Mobec®
Last review date of this leaflet:
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.